Table 1

Patient characteristics with disease type, laboratory parameters, CART cell product including previous therapy, and toxicity treatment

Age (years) at the time of CART infusion5826–75 years
Sex (F:M)6:8
ECOG performance status10–2
Ann Arbor stageIVI–IV
Disease type
 DLBCL6 patients
 DLBCL with CNS involvement3 of 6 patients
 tFL3 patients
 MCL with CNS involvement2 patients
 Lymphoblastic lymphoma1 patient
 Burkitt lymphoma1 patient
 PMBCL1 patient
Peak ICANS31–5
Peak CRS21–4
Peak LDH524 U/L163–17624 U/L (norm 110–220 U/L)
CART cell product
 Axicabtagene ciloleucel—Yescarta7 patients
 Tisagenlecleucel—Kymriah7 patients
Previous treatment
 Previous treatment lines42–8
 Previous ASCT2 patients0
Hospitalization days20.5 days11–29 days
Toxicity treatment
 Corticosteroid start (after CART infusion)14 of 144.5 days1–25 days
 Cumulative dexamethasone dose14 of 14297 mg26–1228 mg
 Cumulative dexamethasone days14 of 1412.5 days3–26 days
 Anakinra start (after CART infusion)14 of 148.5 days5–23 days
 Anakinra dose (100–200 mg subcutaneous)14 of 143 times1–3 times
 Number of patients with CRS grade ≥27 of 14
 Number of patients treated with tocilizumab:7 of 14
 Tocilizumab start (after CART infusion)7 of 74 days1–12 days
 Tocilizumab dose (times 8 mg/kg)7 of 72 times1–3 times
 Patients alive (%)29
 Patients alive (n)4
 Patients deceased (%)71
 Day of death29th day18–198 days
 Cause of death6 of 10 PDs
3 of 10 Infections*
1 of 10 ICANS 5
 Fungal infection
 1 patient: mucormycosis
 Coinfection of fungi and bacteria:
 1 patient: Candida albicans and Pseudomonas aeruginosa
 1 patient: Enterococcus faecalis and fungal infection based on 1–3 beta glucan test
  • Hospitalization days from CART infusion (day 0) to discharge are indicated.

  • ASCT, autologous stem cell transplantation; CNS, central nervous system; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; ICANS, immune effector cell-associated neurotoxicity syndrome; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; tFL, transformed follicular lymphoma.